

Cabenuva Referral Form

Please complete the following and send with clinical documentation to: p: 844.575.1515 | f: 844.797.5050 | e: <u>specialtyreferrals@soleohealth.com</u>

REFERRAL PROCESS	
1. PATIENT INFORMATION	2. PHYSICIAN INFORMATION
Name:	Physician's name:
Address:	License #: NPI #:
City: State: Zip:	DEA #:
Home Phone: Mobile:	Address:
Email:	City: State: Zip:
DOB: Social Security #:	Office Contact:
Gender: ☐ M ☐ F ☐ Nonbinary Height: Weight:	
Allergies*: NKA*: Alternate contact name: Alternate contact phone:	
Alternate contact name: Alternate contact phone: Consent to leave voice message at the patient and/or alternate contact phone Yes No*	
3. DIAGNOSIS ☐ HIV (B20) ☐ Other Diagnosis Has the patient started on oral lead-in therapy of Cabotegravir and Rilpivirine? ☐ No ☐ Yes If yes, what was the date of the first dose? Has the patient demonstrated hypersensitivity to Cabotegravir or Rilpivirine? ☐ No ☐ Yes What is the current viral load?copies/mL	
4. INSURANCE INFORMATION Please submit copies of the front and back of primary and secondary insurance cards with this referral.	
Cabenuva* (Cabotegravir/Rilpivirine)-follow manufacturer dosing guidelines Monthly: Initiation Dose: Inject intramuscularly (Gluteal) Cabotegravir 600 mg (3 mL) and Rilpivirine 900mg (3 mL) Continuation Dose: Inject intramuscularly (Gluteal) once monthly Cabotegravir 400 mg (2 mL) and Rilpivirine 600 mg (2 mL) Comments:	
 ANAPHYLAXIS ORDERS Adults: For mild reaction-administer diphenhydramine 50mg IVP/PO x 1. For severe reactions-administer epinephrine 0.3mg SubQ/IM x 1. May repeat x1 if needed. Contact 911 and monitor vital signs. For severe reaction (airway closure) administer epinephrine. 0.01mg/kg/dose (max 0.3mg) SubQ/IM x 1.	
of adverse effects or complications of therapy. RN to establish, maintain and vascular access device or venipuncture.	
8. \square Dispense as written \square Substitution Permitted	
PHYSICIAN'S SIGNATURE (required):	Date: